Your browser doesn't support javascript.
A Thermostable mRNA Vaccine against COVID-19.
Zhang, Na-Na; Li, Xiao-Feng; Deng, Yong-Qiang; Zhao, Hui; Huang, Yi-Jiao; Yang, Guan; Huang, Wei-Jin; Gao, Peng; Zhou, Chao; Zhang, Rong-Rong; Guo, Yan; Sun, Shi-Hui; Fan, Hang; Zu, Shu-Long; Chen, Qi; He, Qi; Cao, Tian-Shu; Huang, Xing-Yao; Qiu, Hong-Ying; Nie, Jian-Hui; Jiang, Yuhang; Yan, Hua-Yuan; Ye, Qing; Zhong, Xia; Xue, Xia-Lin; Zha, Zhen-Yu; Zhou, Dongsheng; Yang, Xiao; Wang, You-Chun; Ying, Bo; Qin, Cheng-Feng.
  • Zhang NN; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China; School of Medicine, Tsinghua University, Beijing 100084, China.
  • Li XF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Deng YQ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Zhao H; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Huang YJ; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Yang G; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
  • Huang WJ; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.
  • Gao P; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • Zhou C; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Zhang RR; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Guo Y; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Sun SH; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Fan H; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Zu SL; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Chen Q; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • He Q; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
  • Cao TS; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Huang XY; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Qiu HY; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Nie JH; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China.
  • Jiang Y; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • Yan HY; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • Ye Q; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Zhong X; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • Xue XL; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • Zha ZY; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China.
  • Zhou D; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China.
  • Yang X; State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing 102206, China.
  • Wang YC; Division of HIV/AIDS and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), Beijing 102629, China. Electronic address: wangyc@nifdc.org.cn.
  • Ying B; Suzhou Abogen Biosciences Co., Ltd., Suzhou 215123, China. Electronic address: bo.ying@abogenbio.com.
  • Qin CF; State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Academy of Military Medical Sciences, Beijing 100071, China. Electronic address: qincf@bmi.ac.cn.
Cell ; 182(5): 1271-1283.e16, 2020 09 03.
Article in English | MEDLINE | ID: covidwho-666099
ABSTRACT
There is an urgent need for vaccines against coronavirus disease 2019 (COVID-19) because of the ongoing SARS-CoV-2 pandemic. Among all approaches, a messenger RNA (mRNA)-based vaccine has emerged as a rapid and versatile platform to quickly respond to this challenge. Here, we developed a lipid nanoparticle-encapsulated mRNA (mRNA-LNP) encoding the receptor binding domain (RBD) of SARS-CoV-2 as a vaccine candidate (called ARCoV). Intramuscular immunization of ARCoV mRNA-LNP elicited robust neutralizing antibodies against SARS-CoV-2 as well as a Th1-biased cellular response in mice and non-human primates. Two doses of ARCoV immunization in mice conferred complete protection against the challenge of a SARS-CoV-2 mouse-adapted strain. Additionally, ARCoV is manufactured as a liquid formulation and can be stored at room temperature for at least 1 week. ARCoV is currently being evaluated in phase 1 clinical trials.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / RNA, Viral / Viral Vaccines / Vaccines, Synthetic Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: Cell Year: 2020 Document Type: Article Affiliation country: J.cell.2020.07.024

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / RNA, Viral / Viral Vaccines / Vaccines, Synthetic Type of study: Experimental Studies / Prognostic study Topics: Vaccines Language: English Journal: Cell Year: 2020 Document Type: Article Affiliation country: J.cell.2020.07.024